Overview

A Study to Determine the Pharmacokinetics, Pharmacodynamics, and Tolerabiltiy of Betrixaban in Patients With Mild, Moderate, and Severe Renal Impairment

Status:
Completed

Trial end date:
2010-02-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to compare the pharmacokinetics, pharmacodynamics, and tolerability of betrixaban in patients with mild, moderate, and severe renal impairment to healthy volunteers.

Phase:

Phase 1

Details

Lead Sponsor:

Portola Pharmaceuticals

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Betrixaban